Meeting News

Guest Commentary: Resistance to androgen-targeting agents highlights unmet need in prostate cancer

August 10, 2017
In this guest commentary, Leonard J. Appleman, MD, PhD, of the division of hematology/oncology at the University of Pittsburgh
Meeting News

Resuming treatment with cabazitaxel provides ‘option’ in advanced prostate cancer

August 8, 2017
CHICAGO – Retreatment with cabazitaxel demonstrated encouraging activity and acceptable toxicity when used in combination with a new hormonal…
Meeting News

Shorter duration of androgen deprivation therapy reduces side effects in prostate cancer

August 7, 2017
CHICAGO – Reducing the duration of androgen deprivation therapy from 36 to 18 months improved quality of life without affecting survival…
Meeting NewsVideo

VIDEO: Genomic risk system may help treat prostate cancer

July 19, 2017
CHICAGO — The use of a genomic classifier in combination with clinicopathologic variables may provide a valuable prognostic system for distant…
Meeting News

Bone scan index reliably predicts prostate cancer outcomes

July 18, 2017
CHICAGO — An automated bone scan index has been confirmed as a prognostic biomarker of OS, radiographic PFS and skeletal-related events among…
Meeting NewsVideo

VIDEO: LATITUDE, STAMPEDE trials provide ‘practice-changing’ findings in prostate cancer

July 15, 2017
The results of the LATITUDE and STAMPEDE trials presented at the ASCO Annual Meeting position abiraterone acetate “as the new frontline agent…
Meeting News

Enzalutamide enhances PSA response, but not time to PSA progression, vs. abiraterone

June 28, 2017
CHICAGO – Enzalutamide demonstrated a greater PSA response among patients with metastatic, castration-resistant prostate cancer than…
Meeting News

Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment

June 21, 2017
In this guest commentary, Terence Friedlander, MD, discusses the benefits associated with the addition of
Meeting NewsVideo

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy…
Meeting NewsVideo

VIDEO: Immunotherapy agent induces response in prostate cancer

June 20, 2017
CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the…